Xenetic Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Xenetic Biosciences, Inc. on July 8, 2016, covering events occurring on July 1, 2016. The filing details unregistered sales of equity securities and compensatory arrangements involving the Chief Executive Officer and a related party.
Key Financial Metrics and Transactions
- Convertible Note to CEO: Issued a $369,957.51 convertible promissory note to CEO M. Scott Maguire.
- Warrants to CEO: Issued warrants to purchase 37,369 shares of common stock to Mr. Maguire.
- Convertible Note to Pharmsynthez: Issued a $500,000 convertible promissory note to PJSC Pharmsynthez.
- Warrants to Pharmsynthez: Issued warrants to purchase 50,505 shares of common stock to PJSC Pharmsynthez.
- Conversion Price: Both notes are convertible at $4.95 per share.
- Warrant Exercise Price: The lesser of $6.60 or 120% of the price per share in the Company's next capital raise of at least $15 million.
- CEO Compensation: Mr. Maguire's annual salary is $505,735. Historically, 50% was deferred; this filing formalizes the deferral of 50% of salary until the earlier of a NASDAQ listing or September 30, 2016.
Note: The filing does not provide data on revenue, profit, cash flow, margins, total debt, or liquidity positions.
Material Changes and Consideration
The issuance of the Note and Warrants to Mr. Maguire was in consideration for entering into a Deferred Salary Security Agreement, formalizing the deferral of 50% of his accrued salary. The issuance to PJSC Pharmsynthez was in consideration for a $500,000 loan to the Company. The Company granted Mr. Maguire a continuing subordinated security interest in its assets (including inventory, accounts receivable, and intellectual property) as security for the deferred salary.
Outlook, Risks, and Contingencies
- Deferral End Date: Deferred salary becomes due and payable on September 30, 2016, unless a public offering concurrent with a NASDAQ listing occurs earlier.
- Capital Raise Condition: The warrant exercise price is contingent on the Company successfully completing a capital raise of at least $15 million.
- Regulatory Exemption: The Company relied on Section 4(2) of the Securities Act for exemption from registration for these issuances.
Key Facts for Investor Verification
- Verify the Company's ability to repay the $369,957.51 deferred salary obligation by the September 30, 2016 deadline.
- Confirm the status of any ongoing efforts to secure a $15 million capital raise, which impacts the warrant exercise price.
- Assess the impact of the subordinated security interest granted to the CEO on the Company's ability to secure future financing or sell assets.
- Review the terms of the Asset Purchase Agreement with PJSC Pharmsynthez to understand the full scope of the $500,000 loan and related obligations.